Oriven, 37.5 mg, prolonged-release hard capsules
Venlafaxine
Oriven contains the active substance venlafaxine.
Oriven is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRI). Medicines in this group are used to treat depression and other conditions, such as anxiety disorders. The mechanism of action of antidepressants is not fully understood, but they may help by increasing the levels of serotonin and noradrenaline in the brain.
Oriven is used to treat depression in adults. It is also used to treat the following anxiety disorders in adults: generalized anxiety disorder, social phobia (fear or avoidance of social situations), and panic disorder (panic attacks). Proper treatment of depression or anxiety disorders is very important for improving the patient's well-being. If left untreated, the patient's condition may not improve, and their illness may become severe and difficult to treat.
wait at least 7 days after stopping Oriven (see also the section "Oriven and other medicines" and the information in the section "Serotonin syndrome").
Before starting to use Oriven, the patient should discuss it with their doctor or pharmacist if:
Oriven may cause feelings of restlessness or an inability to sit or stand still during the first few weeks of treatment. If such symptoms occur, the patient should inform their doctor.
The patient should not drink alcohol during treatment with Oriven, as it may cause extreme fatigue and loss of consciousness. Taking Oriven with alcohol and/or certain other medicines may increase the severity of depression and other conditions, such as anxiety disorders.
Suicidal thoughts and worsening of depression or anxiety disorders
People with depression and/or anxiety disorders may sometimes have thoughts of self-harm or suicide. Such thoughts may worsen at the start of treatment with antidepressants, as these medicines usually start to work after 2 weeks, and sometimes later. Such thoughts may also occur after reducing the dose or during withdrawal of Oriven.
The occurrence of suicidal thoughts, self-harm, or suicide is more likely if:
If the patient experiences suicidal thoughts or self-harm, they should immediately contact their doctor or go to the hospital.
It may be helpful to inform relatives or friends about the depression or anxiety disorder and ask them to read this leaflet. The patient may ask their relatives or friends for help and ask them to inform them if they notice that the depression or anxiety has worsened or if there are any worrying changes in behavior.
Dry mouth
Dry mouth is reported by 10% of patients treated with venlafaxine. This condition may increase the risk of tooth decay. Therefore, the patient should take special care of their oral hygiene.
Diabetes
Oriven may affect blood sugar levels, and therefore, it may be necessary to adjust the dose of antidiabetic medicines.
Sexual dysfunction
Medicines like Oriven (so-called SNRI) may cause sexual dysfunction (see section 4). In some cases, these symptoms persisted after stopping treatment.
Oriven should not be used in children and adolescents under 18 years of age. It should also be noted that patients under 18 years of age who take medicines in this group are at increased risk of side effects, such as suicidal attempts, suicidal thoughts, and hostility (especially aggression, rebellious behavior, and manifestations of anger). However, the doctor may prescribe this medicine to patients under 18 years of age if they consider it beneficial for them. If the doctor has prescribed this medicine to a patient under 18 years of age, in case of any doubts, the patient should consult their doctor to discuss it. The patient should inform their doctor if any of the above symptoms occur or worsen in patients under 18 years of age taking Oriven.
So far, there is no evidence of the long-term safety of this medicine regarding its impact on growth, maturation, and development of cognitive and behavioral functions in this age group.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The doctor will decide whether to use Oriven with other medicines.
The patient should not start or stop taking other medicines, including over-the-counter medicines, herbal or natural products, without consulting their doctor or pharmacist first.
Irreversible monoamine oxidase inhibitors used to treat depression or Parkinson's disease should not be taken with Oriven. The patient should tell their doctor if they have taken these medicines in the last 14 days (IMAO; see the section "Important information before using Oriven").
Serotonin syndrome
During treatment with venlafaxine, a potentially life-threatening or neuroleptic malignant syndrome-like reaction may occur (see section 4 "Possible side effects"), especially when taken with other medicines.
The subjective and objective symptoms of serotonin syndrome may include the following:
The most severe form of serotonin syndrome may resemble neuroleptic malignant syndrome. Its subjective and objective symptoms include: fever, rapid heartbeat, sweating, muscle stiffness, disorientation, increased muscle enzyme activity (detected in blood tests).
If the patient is taking medicines that may affect heart rhythm, they should tell their doctor.
Examples of such medicines:
The following medicines may also interact with Oriven, and therefore, the patient should use them with caution. It is especially important to inform the doctor if the patient is taking medicines containing:
Oriven should be taken with food (see section 3 "How to use Oriven").
The patient should not drink alcohol during treatment with Oriven. Taking Oriven with alcohol may cause extreme fatigue and loss of consciousness, as well as worsen the symptoms of depression and other conditions, such as anxiety disorders.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before using this medicine. Oriven should only be used after discussing the potential benefits and risks with the doctor.
The patient should make sure that their midwife and/or doctor know that they are taking Oriven. During treatment during pregnancy, similar medicines (SSRI) may increase the risk of a severe condition in newborns called persistent pulmonary hypertension in the newborn (PPHN), causing rapid breathing and bluish discoloration in newborns.
These symptoms usually occur within the first 24 hours after birth. If these symptoms occur in the baby, the patient should immediately contact their midwife and/or doctor.
Taking Oriven at the end of pregnancy may increase the risk of severe postpartum hemorrhage, especially if the patient has a history of bleeding disorders. If the patient is taking Oriven, they should inform their doctor or midwife so that they can provide appropriate advice.
If the patient is taking this medicine during pregnancy, the following symptoms may occur in the baby after birth: poor feeding and breathing difficulties. If the patient is concerned about such symptoms in their newborn, they should contact their doctor and/or midwife, who will be able to provide appropriate advice.
Venlafaxine passes into breast milk. There is a risk of affecting the baby.
Therefore, the patient should discuss this with their doctor, and the doctor will decide whether to stop breastfeeding or stop treatment with this medicine.
The patient should not drive or operate machinery until they know how the medicine affects them.
The 150 mg capsule contains colorants, orange yellow (E 110) and Allura red (E 129), which may cause allergic reactions.
The 225 mg capsule contains the colorant carmoisine (E 122), which may cause allergic reactions.
This medicine should always be used exactly as prescribed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
The usual recommended initial dose of venlafaxine for the treatment of depression, generalized anxiety disorder, and social phobia is 75 mg per day. The doctor may gradually increase this dose, up to a maximum dose of 375 mg, if necessary, for the treatment of depression. In patients with panic disorder, the doctor will prescribe a lower initial dose (37.5 mg) and then gradually increase it. The maximum dose for the treatment of generalized anxiety disorder, social phobia, and panic disorder is 225 mg per day.
Oriven should be taken once a day, at approximately the same time, regardless of whether the medicine is taken in the morning or evening.
The capsules should be swallowed whole with a drink. The capsules should not be divided, crushed, broken, or chewed.
Oriven should be taken with food.
The patient should inform their doctor about any liver or kidney problems, as it may be necessary to adjust the dose of this medicine.
The patient should not stop treatment with this medicine without consulting their doctor (see the section "Stopping Oriven").
In case of taking a higher dose of this medicine than prescribed by the doctor, the patient should immediately contact their doctor or pharmacist.
Overdose may be life-threatening, especially when taken with alcohol and/or certain other medicines (see the section "Oriven and other medicines").
Symptoms of possible overdose may include rapid heartbeat, changes in consciousness (from drowsiness to coma), changes in vision, seizures or convulsions, and vomiting.
In case of missing a dose, the patient should take it as soon as possible. However, if it is almost time for the next dose, the patient should skip the missed dose and take only one dose at the usual time. The patient should not take a double dose to make up for the missed dose. The patient should not take a higher dose in one day than the daily dose of Oriven prescribed by the doctor.
The patient should not stop treatment or reduce the dose without consulting their doctor, even if they feel better. If the doctor decides that it is possible to stop Oriven, they will inform the patient how to do it, gradually reducing the dose. In patients stopping this medicine, especially when stopping treatment abruptly or reducing the dose too quickly, side effects may occur, such as suicidal thoughts, aggression, fatigue, dizziness, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, restlessness, disorientation, ringing in the ears, tingling or rarely a feeling of electric shock, weakness, sweating, seizures or convulsions, or flu-like symptoms, changes in vision, and increased blood pressure (which may cause headache, dizziness, ringing in the ears, sweating, etc.).
The doctor will advise how to gradually stop Oriven. This may take several weeks or months. In some patients, it may be necessary to stop treatment more gradually, over several months or longer. If any of the above symptoms occur or worsen, the patient should consult their doctor.
In case of any further doubts about using this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Oriven can cause side effects, although not everybody gets them.
In case of experiencing any of the following side effects, the patient should stop using Oriven and immediately contact their doctor or go to the nearest hospital's emergency department:
Uncommon ( may affect up to 1 in 100 people)
Rare ( may affect up to 1 in 1,000 people)
Frequency not known ( frequency cannot be estimated from the available data)
Other side effects that the patient should tell their doctor aboutinclude (the frequency of these side effects is included in the list below entitled "Other side effects that may occur"):
Very common ( may affect more than 1 in 10 people)
Common ( may affect up to 1 in 10 people)
Uncommon ( may affect up to 1 in 100 people)
Rare ( may affect up to 1 in 1,000 people)
Very rare ( may affect up to 1 in 10,000 people)
Frequency not known ( frequency cannot be estimated from the available data)
Venlafaxine may sometimes cause side effects that the patient may not be aware of, such as increased blood pressure or abnormal heart rhythm; slight changes in liver enzyme activity, sodium levels, or rarely cholesterol levels in the blood. Even more rarely, venlafaxine may affect platelet function, leading to an increased risk of bruising or bleeding. For this reason, the doctor may recommend regular blood tests, especially during long-term use of Oriven.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw, phone: 22 49-21-301, fax: 22 49-21-309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
There are no special storage instructions for this medicine.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer need. This will help protect the environment.
Capsule shellOriven 37.5 mg prolonged-release hard capsules:
gelatin, titanium dioxide (E 171), iron oxide black (E 172), iron oxide red (E 172), iron oxide yellow (E 172), ink (shellac, iron oxide red (E 172)).
Oriven 75 mg prolonged-release hard capsules:
gelatin, titanium dioxide (E 171), iron oxide black (E 172), iron oxide red (E 172), ink (shellac, iron oxide red (E 172)).
Oriven 150 mg prolonged-release hard capsules:
gelatin, titanium dioxide (E 171), orange yellow (E 110), Allura red (E 129), brilliant blue (E 133), ink (shellac, titanium dioxide (E 171)).
Oriven 225 mg prolonged-release hard capsules:
gelatin, titanium dioxide (E 171), carmoisine (E 122), ink (shellac, indigo carmine (E 132), propylene glycol, concentrated ammonia solution).
Prolonged-release hard capsules
Oriven 37.5 mg:
light gray and peach-colored, opaque, size "3", hard gelatin capsule with broad and thin red stripes around both parts of the capsule. The capsule is filled with 3 small coated tablets, which are white or almost white, round, and biconvex.
Oriven 75 mg:
peach-colored, opaque, size "1", hard gelatin capsule with broad and thin red stripes around both parts of the capsule. The capsule is filled with 6 small coated tablets, which are white or almost white, round, and biconvex.
Oriven 150 mg:
dark orange-colored, opaque, size "0", hard gelatin capsule with broad and thin white stripes around both parts of the capsule. The capsule is filled with 12 small coated tablets, which are white or almost white, round, and biconvex.
Oriven 225 mg:
pink-colored, opaque, size "00", hard gelatin capsule with broad and thin blue stripes around both parts of the capsule. The capsule is filled with 18 small coated tablets, which are white or almost white, round, and biconvex.
Pack sizes:
For 37.5 mg, 75 mg, and 150 mg: 28 and 98 prolonged-release capsules in blisters.
For 225 mg: 28 prolonged-release capsules in blisters, in a cardboard box.
Not all pack sizes may be marketed.
Orion Corporation
Orionintie 1
02200 Espoo
Finland
Orion Corporation, Orion Pharma
Orionintie 1
02200 Espoo
Finland
Orion Corporation, Orion Pharma
Joensuunkatu 7
24100 Salo
Finland
To obtain more detailed information about this medicine, the patient should contact the local representative of the marketing authorization holder:
Orion Pharma Poland Sp. z o. o.
kontakt@orionpharma.info.pl
Date of last revision of the leaflet:10.05.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.